eXoZymes, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a EXOZ research report →
Price Chart
About the company
eXoZymes, Inc. operates as a development stage biotechnology company. It focuses on the development of enzyme modules and cell-free exozyme biosolutions for synthetic biology manufacturing.
- CEO
- Michael Heltzen
- IPO
- 2024
- Employees
- 32
- HQ
- Monrovia, CA, US
Get TickerSpark's AI analysis on EXOZ
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $51.23M
- P/E
- -4.60
- PEG
- 0.76
- P/S
- 0.00
- P/B
- 13.08
- EV/EBITDA
- -4.41
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -292.13%
- ROIC
- -155.79%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+100.0%
- Op Income
- $-9,716,471
- Net Income
- $-9,158,734-56.3%
- EPS
- $-1.09-51.4%
- OCF Growth
- +23.6%
- FCF Growth
- +25.1%
- 52W High
- $18.40
- 52W Low
- $4.35
- 50D MA
- $6.04
- 200D MA
- $8.40
- Beta
- 3.19
- RSI (14)
- 36
- Avg Volume
- 6.85K
No earnings-call transcripts are available for EXOZ yet.
- Free Float
- 26.7%
- Shares Outstanding
- 9.28M
- Float Shares
- 2.48M
of shares held by institutions
7 13F filers
Buy/sell ratio 3.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Capital Management LLC | 54.98K | ▲ 32.80K |
| Vanguard Group Inc | 31.52K | ▲ 5.54K |
| Davidson Kahn Capital Management, LLC | 25.00K | ▲ 25.00K |
| Geode Capital Management, LLC | 23.41K | ▲ 1.51K |
| Blackrock, Inc. | 9.61K | ▲ 2.81K |
| Vanguard Fiduciary Trust Co | 9.43K | 0 |
| Morgan Stanley | 1.25K | 0 |
| Tower Research Capital LLC (Trc) | 349 | ▼ 968 |
| Mercer Global Advisors Inc /Adv | 250 | ▲ 250 |
| Ubs Group AG | 203 | ▲ 179 |
| Barclays PLC | 75 | ▲ 75 |
Held by 18 ETFs
Biggest fund positions in EXOZ by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Sep 14, 26 | Nawaz Fouad | other | 45,000 |
| Aug 26, 26 | Heltzen Michael | buy | 4 |
| Aug 26, 26 | Heltzen Michael | buy | 251 |
| Aug 26, 26 | Heltzen Michael | buy | 250 |
| Aug 25, 26 | Heltzen Michael | buy | 250 |
| Aug 25, 26 | Heltzen Michael | buy | 100 |
| Aug 19, 26 | Heltzen Michael | other | 8,841 |
| Aug 19, 26 | Perriman Damien Alan | other | 19,612 |
| Aug 19, 26 | Perriman Damien Alan | other | 19,612 |
| Aug 19, 26 | Korman Tyler Paz | other | 32,964 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our EXOZ coverage
Recent articles, reports, and earnings notes.
No research on EXOZ yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate EXOZ report →Water Tower Research Publishes Initiation of Coverage Report on eXoZymes, Inc., "Converting Cell-Free Science into a Scalable and Repeatable Commercial Opportunity"
thenewswire.com · Oct 2
Head to Head Contrast: Iovance Biotherapeutics (NASDAQ:IOVA) vs. eXoZymes (NASDAQ:EXOZ)
defenseworld.net · Sep 17
eXoZymes Selects Curia as Commercial-Scale Manufacturing Partner for NCT
accessnewswire.com · Sep 8
eXoZymes Q2 Earnings Call Highlights
defenseworld.net · Aug 22
eXoZymes Q2 Earnings Call Highlights
marketbeat.com · Aug 20
eXoZymes Reports Second Quarter 2026 Results and Provides Business Update at 5PM ET Today
accessnewswire.com · Aug 20
eXoZymes' NCT Process Achieves 10-fold Productivity Increase, Advancing Beyond Original Commercial-scale Economic Targets
accessnewswire.com · Aug 18
eXoZymes to Host Second Quarter 2026 Update Conference Call on Thursday, August 20, 2026
accessnewswire.com · Aug 11
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.